IDEAS · Improving Drug Efficacy with next-generation AmorphouS materials and trained experts

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Approximately 70–90% of all new chemical entities and drug molecules under development are reported to have poor aqueous solubility. Since 2000 amorphous forms emerged as one of the most popular strategies in the pharmaceutical industry to enhance the solubility and bioavailability of challenging drugs. However, due to the intrinsic instability of amorphous materials, only a limited number of commercially available products have been developed so far by Europe’s biotech and pharmaceutical industries. Building on recent technological advances and scientific discoveries by the IDEAS partners, we are convinced that overcoming thismajor bottleneck requires a more rational approach to the elusive amorphous physical state, transcending the current empirical methods that hinder innovation. This effort demands a unified project bringing together the cross-disciplinary expertise of academic research groups in materials science, physics, chemistry, and pharmacy, alongside industry partners. The network comprises a consortium of 10 beneficiaries (7 universities, 2 large companies, and 1 SME) and 6 associated partners (1 academic and 5 industrial) from 10 EU countries. The IDEAS Doctoral Network is designed to empower a new generation of young scientists in the field of amorphous pharmaceutical systems, strengthening Europe’s biotech/pharma industry and academic innovation capacity. Through this programme, we will train 15 doctoral candidates (DCs) to address key challenges associated with amorphous materials. The fellows will collaborate to develop eco-friendly manufacturing technologies for amorphous materials, establish science-based control over material properties, and explore a wide range of materials to achieve efficient production of high-quality amorphous formulations. This advanced research-driven training will be further enriched with opportunities to develop a broad spectrum of personal, organisational, and impactful skills.

Original text from CORDIS.

Participants

• UNIVERSITE DE LILLE · LilleCoordinatorFrance
• ACCELOPMENT SCHWEIZ AG · ZurichSwitzerland
• F1 Pharma S.A. · KrakowCity levelPoland
• INSTITUTO SUPERIOR TECNICO · LisboaPortugal
• JANSSEN PHARMACEUTICA NV · BeerseBelgium
• LINARI ENGINEERING SRL · PISAItaly
• MYBIOTECH GMBH · UberherrnGermany
• PHYSIOLUTION GMBH · GreifswaldGermany
• THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinIreland
• UCB PHARMA SA · Bruxelles / BrusselBelgium
• UNIVERSIDADE NOVA DE LISBOA · LisboaPortugal
• UNIVERSITA DI PISA · PisaItaly
• UNIVERSITAT POLITECNICA DE CATALUNYA · BARCELONASpain
• UNIVERSITE CATHOLIQUE DE LOUVAIN · LOUVAIN LA NEUVEBelgium
• UNIWERSYTET SLASKI W KATOWICACH · KATOWICEPoland
• ZENTIVA KS · PRAHACzechia

Links

• View on CORDIS
• DOI: 10.3030/101312168